Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
Authors:
- Aleksandra BożykABAleksandra Bożyk
- Paweł KrawczykPKPaweł Krawczyk
- Katarzyna ReszkaKRKatarzyna Reszka
- Kinga KrukowskaKKKinga Krukowska
- Agnieszka KolakAKAgnieszka Kolak
- Sławomir MańdziukSMSławomir Mańdziuk
- Kamila Wojas-KrawczykKWKamila Wojas-Krawczyk
- Rodryg RamlauRRRodryg Ramlau
- Janusz MilanowskiJanusz Milanowski
Open Access
- 24 March 2021
- journal article
- research article
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 18 (5) , 1221-1230
Abstract
Introduction: Detection of abnormalities in the KRAS, NRAS and BRAF genes is extremely important for proper qualification of colorectal cancer (CRC) patients for therapy with anti-EGFR (epidermal growth factor receptor) monoclonal antibodies. However, data about prevalence of mutations in these genes, in different localizations of CRC tumors, are limited.Material and methods: We examined the frequency of mutations in the KRAS, NRAS and BRAF genes in 500 Caucasian CRC patients (200 women and 300 men, median age 66 years). DNA was isolated from formalin-fixed, paraffin-embedded (FFPE) tissues using a Qiagen QIAamp DNA FFPE-kit. Analysis of mutations was carried out using the KRAS/BRAF, NRAS and BRAF Mutation Analysis Kit for Real-Time PCR (EntroGen) with the Cobas 480 realtime PCR apparatus (Roche Diagnostics).Results: KRAS mutations were detected in 190 patients (38%), NRAS mutations in 20 patients (4%), and BRAF mutations in 24 patients (4.8%). There were no associations between age of CRC patients and frequency of KRAS, NRAS and BRAF gene mutations. These mutations were significantly more often diagnosed in women (55.5%) than in men (41%, p < 0.005). Tumors of the rectum and sigmoideum were the most often observed in both groups of CRC patients – with and without KRAS, NRAS and BRAF gene mutations. However, transverse colon, ascending colon and cecum cancers were the most often affected by mutations.Conclusions: Our study showed that the occurrence of mutations in the KRAS, NRAS and BRAF genes is not accidental and depends on the location of CRC tumors.Keywords
This publication has 23 references indexed in Scilit:
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal CancerJournal of Clinical Oncology, 2015
- Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumorsMolecular and Clinical Oncology, 2014
- Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancerAnnals of Oncology, 2014
- Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and PreventionInternational Journal of Molecular Sciences, 2013
- KRAS Mutational Status in Japanese Patients with Colorectal Cancer: Results from a Nationwide, Multicenter, Cross-sectional StudyJapanese Journal of Clinical Oncology, 2013
- Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectumGut, 2012
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation StatusJournal of Clinical Oncology, 2011
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studyAnnals of Oncology, 2011
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME StudyJournal of Clinical Oncology, 2010
- NRAS Mutations Are Rare in Colorectal CancerDiagnostic Molecular Pathology, 2010